Blood Proteomics Complements Rare Disease Genome Sequencing
Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 10, 2026
This research validates the commercial potential of proteomics platforms and could accelerate investment in companies developing blood-based protein diagnostics and multi-omics tools. It may also increase demand for genomic and proteomic testing services, benefiting life sciences tools providers and diagnostics companies.
Researchers from Queen Mary University of London, the Berlin Institute of Health at Charité (BIH), and United Kingdom — Genomics England have published a study in Science Translational Medicine showing that measuring proteins in the blood can provide important additional clues about the effects of genetic variants, helping to identify diagnoses and potential new disease-causing genes that genome sequencing alone has been unable to resolve. The study analyzed blood samples from people with rare diseases who remained without a genetic diagnosis following analysis through United Kingdom — Genomics England's 100,000 Genomes Project. By measuring nearly 1,500 proteins in blood and combining this information with genomic data, the researchers were able to resolve previously uncertain genetic findings and provide evidence supporting diagnoses for some patients. The approach also helped identify candidate genetic variants and genes that could potentially explain the conditions of other patients and warrant further investigation. The findings provide proof-of-principle that large-scale blood proteomics could complement genome sequencing in the diagnosis of rare disease. The team led by Claudia Langenberg, head of the BIH Computational Medicine research group and director of PHURI at Queen Mary University of London, found the approach particularly useful in patients with hereditary haemorrhagic telangiectasia (HHT), a rare inherited disorder affecting blood vessels. One example involved TIE1, a protein involved in blood vessel function, where researchers identified a rare genetic variant in a patient with a previously unexplained inherited cardiac disorder who also had exceptionally low levels of the TIE1 protein in their blood. The researchers stress that findings such as this represent candidate gene-disease links requiring further evidence rather than confirmed new causes of disease. They emphasize that further studies are needed to confirm their findings and interpretation, and that larger studies across a wider range of rare diseases and more diverse populations will now be needed.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard